-
Mashup Score: 974The gut microbiome associates with phenotypic manifestations of post-acute COVID-19 syndrome - 8 hour(s) ago
Current understanding of the heterogeneity of post-acute COVID-19 syndrome (PACS) is limited. Examining the fecal microbiome in subjects with PACS, Su et al. uncover an association between the gut microbiome and the phenotypic manifestations of PACS. Gut-microbiome-based multi-label machine learning accurately predicts upcoming long-term symptoms after acute COVID-19.
Source: www.cell.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 04 Years In, a Sobering Look at Long COVID Progress - 2 day(s) ago
Long COVID is still a disease diagnosed by figuring out what a patient does not have. Symptom management is the only treatment now.
Source: www.mdedge.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 968The gut microbiome associates with phenotypic manifestations of post-acute COVID-19 syndrome - 2 day(s) ago
Current understanding of the heterogeneity of post-acute COVID-19 syndrome (PACS) is limited. Examining the fecal microbiome in subjects with PACS, Su et al. uncover an association between the gut microbiome and the phenotypic manifestations of PACS. Gut-microbiome-based multi-label machine learning accurately predicts upcoming long-term symptoms after acute COVID-19.
Source: www.cell.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 0
Investigators at the Centers for Disease Control and Prevention assessed the prevalence of long COVID among adults throughout the United States.
Source: www.infectiousdiseaseadvisor.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 10
With a still-emerging understanding of the syndrome’s biology, researchers are braiding basic discoveries into treatment studies as they go
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 2406
Our recent study using data from more than 20 million participants has shown that COVID-19 vaccines consistently prevent long COVID symptoms in adults, with meta-analytic calibrated subdistribution hazard ratio (sHRs) of 0·54 (95% CI 0·44–0·67) in CPRD GOLD, 0·48 (0·34–0·68) in CPRD AURUM, 0·71 (0·55–0·91) in SIDIAP, and 0·59 (0·40–0·87) in CORIVA.1 In addition, when considering post-COVID thromboembolic and cardiovascular complications as outcomes of interest, recently published data have shown that vaccination with any COVID-19 first vaccine dose (ChAdOx1, BNT162b2, and mRNA-1273) is associated with reduced risk of post-acute heart failure (0·45 [0·38–0·53] 0–30 days after SARS-CoV-2 infection; 0·61 [0·51–0·73] 91–180 days after SARS-CoV-2 infection), venous thromboembolism (sHR 0·22 [95% CI 0·17–0·29] 0–30 days after SARS-CoV-2 infection; 0·53 [0·40–0·70] 91–180 days after SARS-CoV-2 infection), and arterial thrombosis (0·53 [0·44–0·63] 0–30 days after SARS-CoV-2 infection; 0·72 [0·
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 3190Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study - 12 day(s) ago
Objective To investigate the effectiveness of primary covid-19 vaccination (first two doses and first booster dose within the recommended schedule) against post-covid-19 condition (PCC). Design Population based cohort study. Setting Swedish Covid-19 Investigation for Future Insights—a Population Epidemiology Approach using Register Linkage (SCIFI-PEARL) project, a register based cohort study in Sweden. Participants All adults (≥18 years) with covid-19 first registered between 27 December 2020 and 9 February 2022 (n=589 722) in the two largest regions of Sweden. Individuals were followed from a first infection until death, emigration, vaccination, reinfection, a PCC diagnosis (ICD-10 diagnosis code U09.9), or end of follow-up (30 November 2022), whichever came first. Individuals who had received at least one dose of a covid-19 vaccine before infection were considered vaccinated. Main outcome measure The primary outcome was a clinical diagnosis of PCC. Vaccine effectiveness against PCC w
Source: www.bmj.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 2348
Our recent study using data from more than 20 million participants has shown that COVID-19 vaccines consistently prevent long COVID symptoms in adults, with meta-analytic calibrated subdistribution hazard ratio (sHRs) of 0·54 (95% CI 0·44–0·67) in CPRD GOLD, 0·48 (0·34–0·68) in CPRD AURUM, 0·71 (0·55–0·91) in SIDIAP, and 0·59 (0·40–0·87) in CORIVA.1 In addition, when considering post-COVID thromboembolic and cardiovascular complications as outcomes of interest, recently published data have shown that vaccination with any COVID-19 first vaccine dose (ChAdOx1, BNT162b2, and mRNA-1273) is associated with reduced risk of post-acute heart failure (0·45 [0·38–0·53] 0–30 days after SARS-CoV-2 infection; 0·61 [0·51–0·73] 91–180 days after SARS-CoV-2 infection), venous thromboembolism (sHR 0·22 [95% CI 0·17–0·29] 0–30 days after SARS-CoV-2 infection; 0·53 [0·40–0·70] 91–180 days after SARS-CoV-2 infection), and arterial thrombosis (0·53 [0·44–0·63] 0–30 days after SARS-CoV-2 infection; 0·72 [0·
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 78
Our recent study using data from more than 20 million participants has shown that COVID-19 vaccines consistently prevent long COVID symptoms in adults, with meta-analytic calibrated subdistribution hazard ratio (sHRs) of 0·54 (95% CI 0·44–0·67) in CPRD GOLD, 0·48 (0·34–0·68) in CPRD AURUM, 0·71 (0·55–0·91) in SIDIAP, and 0·59 (0·40–0·87) in CORIVA.1 In addition, when considering post-COVID thromboembolic and cardiovascular complications as outcomes of interest, recently published data have shown that vaccination with any COVID-19 first vaccine dose (ChAdOx1, BNT162b2, and mRNA-1273) is associated with reduced risk of post-acute heart failure (0·45 [0·38–0·53] 0–30 days after SARS-CoV-2 infection; 0·61 [0·51–0·73] 91–180 days after SARS-CoV-2 infection), venous thromboembolism (sHR 0·22 [95% CI 0·17–0·29] 0–30 days after SARS-CoV-2 infection; 0·53 [0·40–0·70] 91–180 days after SARS-CoV-2 infection), and arterial thrombosis (0·53 [0·44–0·63] 0–30 days after SARS-CoV-2 infection; 0·72 [0·
Source: www.thelancet.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 2232
Our recent study using data from more than 20 million participants has shown that COVID-19 vaccines consistently prevent long COVID symptoms in adults, with meta-analytic calibrated subdistribution hazard ratio (sHRs) of 0·54 (95% CI 0·44–0·67) in CPRD GOLD, 0·48 (0·34–0·68) in CPRD AURUM, 0·71 (0·55–0·91) in SIDIAP, and 0·59 (0·40–0·87) in CORIVA.1 In addition, when considering post-COVID thromboembolic and cardiovascular complications as outcomes of interest, recently published data have shown that vaccination with any COVID-19 first vaccine dose (ChAdOx1, BNT162b2, and mRNA-1273) is associated with reduced risk of post-acute heart failure (0·45 [0·38–0·53] 0–30 days after SARS-CoV-2 infection; 0·61 [0·51–0·73] 91–180 days after SARS-CoV-2 infection), venous thromboembolism (sHR 0·22 [95% CI 0·17–0·29] 0–30 days after SARS-CoV-2 infection; 0·53 [0·40–0·70] 91–180 days after SARS-CoV-2 infection), and arterial thrombosis (0·53 [0·44–0·63] 0–30 days after SARS-CoV-2 infection; 0·72 [0·
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet
The gut microbiome and #LongCovid: "Gut microbiome-based multi-label machine learning accurately predicts upcoming long-term symptoms after acute COVID19." https://t.co/zQWOEQY5bm @cellhostmicrobe by @Siew_C_Ng @CUHKMedicine and colleagues https://t.co/a1t3R98eD9